the Vivakor team, "In the case of each of these gentlemen, Vivakor is quite fortunate to be able to draw on their experience and incredible wealth of knowledge in their respective fields. Dr. Lin is, literally, an icon in his field and his contribution to our scientific research cannot be underestimated. Dr. Chen brings the marriage of science and business acumen to the Board of Directors that will help guide its decisions well into the future. We are a stronger company with their presence."
About Vivakor, Inc.
Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
This press release may contain forward-looking statements which may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
<Page: 1 2 3 Related biology technology :1
. Vivakor, Inc. Announces Stock Dividend2
. Vivakor Confirms Record Date of Stock Dividend3
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients4
. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 265
. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering6
. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.7
. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets8
. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results9
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain10
. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter11
. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer